文献速递鼻科

直接口服抗凝药与华法林相关鼻出血的管理与结局比较

Management and outcome of epistaxis under direct oral anticoagulants: a comparison with warfarin.
PubMed 文献 · Int Forum Allergy Rhinol · 2018-10-03

该回顾性队列研究在德国三级转诊中心纳入677例鼻出血患者,其中159例使用维生素K拮抗剂、49例使用直接口服抗凝药。两组在年龄、性别、生命体征、血液检查、出血部位及管理方式上均无显著差异,住院率与住院时长亦相当。结论提示直接口服抗凝药患者的鼻出血并未更严重或需要更侵入性治疗。

要点

  • 直接口服抗凝药相关鼻出血的严重程度与华法林相关鼻出血相当。
  • 两组住院率(37.1% vs 24.5%)和住院时长(3.5±2.1天 vs 3.8±3.3天)无显著差异。
  • 相当比例华法林患者INR未在目标范围内,提示维生素K拮抗剂监测问题。

核心结论

  • 直接口服抗凝药患者的鼻出血并未比华法林患者更严重或需要更侵入性治疗。
  • 相当比例使用维生素K拮抗剂的患者INR未在目标范围内。

研究设计与样本

  • 德国三级转诊中心的回顾性队列研究,纳入1年期内所有住院患者。
  • 共677例患者,其中159例使用维生素K拮抗剂,49例使用直接口服抗凝药。

主要发现

  • 两组年龄(p=0.592)、性别(p=0.372)、生命体征、血液检查、出血部位(p=0.372)无显著差异。
  • 两组鼻出血管理方式可比(p=0.399)。
  • 住院率37.1% vs 24.5%(p=0.145),住院时长3.5±2.1天 vs 3.8±3.3天(p=0.650),均无显著差异。

临床怎么用

  • 直接口服抗凝药相关鼻出血可按与华法林相关鼻出血类似的流程管理。
  • 使用维生素K拮抗剂的患者需关注INR是否在目标范围内。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Epistaxis is one of the more common reasons for emergency room visits. The main risk factor for epistaxis is anticoagulant therapy. Until recently, the main culprit was oral intake of a vitamin K antagonist, such as warfarin, which has a number of side effects. Even more recently, several direct oral anticoagulants, rivaroxaban and dabigatran, have been approved for use. We investigated the possible differences between treatment of epistaxis with direct oral anticoagulants and vitamin K antagonists. METHODS: We conducted a retrospective cohort study at a tertiary referral center in Germany. All patients who were admitted within a 1-year period were included. Patient files were used to obtain the information. RESULTS: Overall, 677 patients were included in our study. Of these, 159 had been treated with vitamin K antagonists and 49 with direct oral anticoagulants. There were no significant differences in terms of age (p = 0.592), sex (p = 0.372), vital signs, bloodwork, or location of bleeding (p = 0.372). Management of epistaxis between the groups was also comparable (p = 0.399), with similar hospital admission rates (37.1% vs 24.5%; p = 0.145) and duration of stay (3.5 ± 2.1 days vs 3.8 ± 3.3 days; p = 0.650). CONCLUSION: We found no evidence to suggest epistaxis is more severe or requires more invasive therapy in patients given direct oral anticoagulants. A significant proportion of patients on vitamin K antagonists were not within the target range for international normalized ratio, highlighting one of the main issues with oral anticoagulation by vitamin K antagonists.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Send T, Bertlich M, Horlbeck F, et al. Management and outcome of epistaxis under direct oral anticoagulants: a comparison with warfarin. Int Forum Allergy Rhinol. 2018. PMID: 30281938. doi:10.1002/alr.22210

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。